Back to Newsroom

GlobeImmune Announces Evaluation of Strategic Alternatives and Corporate Restructuring

LOUISVILLE, CO–(Marketwired – June 10, 2015) – GlobeImmune, Inc. (NASDAQ: GBIM) today announced that it is evaluating strategic options for the company. In conjunction with this process, the Board has authorized eliminating the majority of positions in its workforce. These steps are not expected to have an impact on ongoing clinical trials being conducted by its collaborators in oncology and hepatitis B.

Click here to read more